AMAG Pharmaceuticals Inc. (AMAG) Stock Rating Reaffirmed by Leerink Swann
AMAG Pharmaceuticals Inc. (NASDAQ:AMAG)‘s stock had its “outperform” rating reissued by equities research analysts at Leerink Swann in a research report issued to clients and investors on Thursday. They presently have a $36.00 price target on the specialty pharmaceutical company’s stock. Leerink Swann’s price objective would suggest a potential upside of 52.80% from the stock’s current price.
Several other analysts have also recently issued reports on AMAG. Zacks Investment Research upgraded AMAG Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 5th. Jefferies Group cut their price objective on AMAG Pharmaceuticals from $58.00 to $45.00 and set a “buy” rating on the stock in a research note on Wednesday, August 10th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. AMAG Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $36.33.
Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) opened at 23.56 on Thursday. The firm’s market capitalization is $804.67 million. The stock has a 50 day moving average price of $24.05 and a 200 day moving average price of $23.94. AMAG Pharmaceuticals has a 12-month low of $17.92 and a 12-month high of $42.49.
AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.20 by $0.25. AMAG Pharmaceuticals had a positive return on equity of 13.98% and a negative net margin of 4.87%. The firm had revenue of $127.40 million for the quarter, compared to analysts’ expectations of $128.52 million. During the same quarter in the prior year, the firm posted $1.12 earnings per share. AMAG Pharmaceuticals’s revenue for the quarter was up 46.7% compared to the same quarter last year. Analysts predict that AMAG Pharmaceuticals will post $5.55 EPS for the current fiscal year.
Institutional investors have recently bought and sold shares of the stock. BlackRock Fund Advisors raised its position in AMAG Pharmaceuticals by 109.2% in the first quarter. BlackRock Fund Advisors now owns 2,930,434 shares of the specialty pharmaceutical company’s stock valued at $68,572,000 after buying an additional 1,529,853 shares during the period. EverPoint Asset Management LLC bought a new position in AMAG Pharmaceuticals during the second quarter valued at approximately $18,658,000. Credit Capital Investments LLC raised its position in AMAG Pharmaceuticals by 1,691.2% in the second quarter. Credit Capital Investments LLC now owns 713,126 shares of the specialty pharmaceutical company’s stock valued at $713,000 after buying an additional 673,313 shares during the period. Greywolf Capital Management LP bought a new position in AMAG Pharmaceuticals during the second quarter valued at approximately $15,843,000. Finally, Janus Capital Management LLC raised its position in AMAG Pharmaceuticals by 20.1% in the second quarter. Janus Capital Management LLC now owns 3,222,639 shares of the specialty pharmaceutical company’s stock valued at $77,084,000 after buying an additional 538,322 shares during the period.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Stock Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.